MedTrace Logo

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

NCT04984356 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-09-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).

Conditions

  • T-cell Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma

Interventions

BIOLOGICAL

WU-CART-007

A single IV infusion of WU-CART-007 Cells on Day 1

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wugen, Inc.

    lead INDUSTRY

Principal Investigators

  • Cherry Thomas, MD · Wugen, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-14
Primary Completion
2024-08-08
Completion
2024-08-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04984356 on ClinicalTrials.gov